Pooled testing for COVID-19 diagnosis by real-time RT-PCR: A multi-site comparative evaluation of 5- & 10-sample pooling.


Journal

The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701

Informations de publication

Date de publication:
Historique:
pubmed: 8 9 2020
medline: 30 9 2020
entrez: 7 9 2020
Statut: ppublish

Résumé

Public health and diagnostic laboratories are facing huge sample loads for COVID-19 diagnosis by real-time reverse transcription-polymerase chain reaction (RT-PCR). High sensitivity of optimized real-time RT-PCR assays makes pooled testing a potentially efficient strategy for resource utilization when positivity rates for particular regions or groups of individuals are low. We report here a comparative analysis of pooled testing for 5- and 10-sample pools by real-time RT-PCR across 10 COVID-19 testing laboratories in India. Ten virus research and diagnostic laboratories (VRDLs) testing for COVID-19 by real-time RT-PCR participated in this evaluation. At each laboratory, 100 nasopharyngeal swab samples including 10 positive samples were used to create 5- and 10-sample pools with one positive sample in each pool. RNA extraction and real-time RT-PCR for SARS-CoV-2-specific E gene target were performed for individual positive samples as well as pooled samples. Concordance between individual sample testing and testing in the 5- or 10-sample pools was calculated, and the variation across sites and by sample cycle threshold (C A total of 110 each of 5- and 10-sample pools were evaluated. Concordance between the 5-sample pool and individual sample testing was 100 per cent in the C Results from this multi-site assessment suggest that pooling five samples for SARS-CoV-2 detection by real-time RT-PCR may be an acceptable strategy without much loss of sensitivity even for low viral loads, while with 10-sample pools, there may be considerably higher numbers of false negatives. However, testing laboratories should perform validations with the specific RNA extraction and RT-PCR kits in use at their centres before initiating pooled testing.

Sections du résumé

BACKGROUND & OBJECTIVES OBJECTIVE
Public health and diagnostic laboratories are facing huge sample loads for COVID-19 diagnosis by real-time reverse transcription-polymerase chain reaction (RT-PCR). High sensitivity of optimized real-time RT-PCR assays makes pooled testing a potentially efficient strategy for resource utilization when positivity rates for particular regions or groups of individuals are low. We report here a comparative analysis of pooled testing for 5- and 10-sample pools by real-time RT-PCR across 10 COVID-19 testing laboratories in India.
METHODS METHODS
Ten virus research and diagnostic laboratories (VRDLs) testing for COVID-19 by real-time RT-PCR participated in this evaluation. At each laboratory, 100 nasopharyngeal swab samples including 10 positive samples were used to create 5- and 10-sample pools with one positive sample in each pool. RNA extraction and real-time RT-PCR for SARS-CoV-2-specific E gene target were performed for individual positive samples as well as pooled samples. Concordance between individual sample testing and testing in the 5- or 10-sample pools was calculated, and the variation across sites and by sample cycle threshold (C
RESULTS RESULTS
A total of 110 each of 5- and 10-sample pools were evaluated. Concordance between the 5-sample pool and individual sample testing was 100 per cent in the C
INTERPRETATION & CONCLUSIONS CONCLUSIONS
Results from this multi-site assessment suggest that pooling five samples for SARS-CoV-2 detection by real-time RT-PCR may be an acceptable strategy without much loss of sensitivity even for low viral loads, while with 10-sample pools, there may be considerably higher numbers of false negatives. However, testing laboratories should perform validations with the specific RNA extraction and RT-PCR kits in use at their centres before initiating pooled testing.

Identifiants

pubmed: 32893844
pii: 294376
doi: 10.4103/ijmr.IJMR_2304_20
pmc: PMC7853252
doi:

Substances chimiques

COVID-19 Vaccines 0
Covid-19 aAPC vaccine 0
RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

88-94

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Déclaration de conflit d'intérêts

None

Références

Sci Adv. 2020 Sep 11;6(37):
pubmed: 32917716
J Clin Microbiol. 2012 Mar;50(3):891-6
pubmed: 22205820
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Med Virol. 2020 Oct;92(10):1988-1994
pubmed: 32330297
J Med Virol. 2020 Nov;92(11):2306-2307
pubmed: 32369202
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):216-225
pubmed: 32242875
Lancet Infect Dis. 2020 Nov;20(11):1231-1232
pubmed: 32530425
Rev Chilena Infectol. 2020 Jun;37(3):276-280
pubmed: 32853320
Am J Clin Pathol. 2020 May 5;153(6):715-718
pubmed: 32304208
Bull World Health Organ. 2020 Sep 01;98(9):590-598
pubmed: 33012859
Clin Infect Dis. 2020 Nov 19;71(16):2073-2078
pubmed: 32358960
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835

Auteurs

Ira Praharaj (I)

Divsion of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

Amita Jain (A)

Department of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

Mini Singh (M)

Department of Virology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

Anukumar Balakrishnan (A)

ICMR-National Institute of Virology, Kerala Unit, Alappuzha, Kerala, India.

Rahul Dhodapkar (R)

Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.

Biswajyoti Borkakoty (B)

Regional Medical Research Centre, Dibrugarh, Assam, India.

Munivenkatappa Ashok (M)

ICMR-National Institute of Virology, Bangalore Unit, Bengaluru, Karnataka, India.

Pradeep Das (P)

ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India.

Debasis Biswas (D)

Department of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.

Usha Kalawat (U)

Department of Microbiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.

Jyotirmayee Turuk (J)

ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.

A P Sugunan (AP)

ICMR-National Institute of Virology, Kerala Unit, Alappuzha, Kerala, India.

Shantanu Prakash (S)

Department of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

Anirudh K Singh (AK)

Department of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.

Rajamani Barathidasan (R)

Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.

Subhra Subhadra (S)

ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.

Jyotsnamayee Sabat (J)

ICMR-Regional Medical Research Centre, Bhubaneswar, Odisha, India.

M J Manjunath (MJ)

ICMR-National Institute of Virology, Bangalore Unit, Bengaluru, Karnataka, India.

Poonam Kanta (P)

Department of Virology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

Nagaraja Mudhigeti (N)

Department of Microbiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India.

Rahul Hazarika (R)

Regional Medical Research Centre, Dibrugarh, Assam, India.

Hricha Mishra (H)

Department of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

Kumar Abhishek (K)

ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India.

C Santhalembi (C)

ICMR-National Institute of Virology, Kerala Unit, Alappuzha, Kerala, India.

Manas Ranjan Dikhit (MR)

ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, Bihar, India.

Neetu Vijay (N)

Department of Health Research, Ministry of Health & Family Welfare, New Delhi, India.

Jitendra Narayan (J)

Department of Health Research, Ministry of Health & Family Welfare, New Delhi, India.

Harmanmeet Kaur (H)

Department of Health Research, Ministry of Health & Family Welfare, New Delhi, India.

Sidhartha Giri (S)

Divsion of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

Nivedita Gupta (N)

Divsion of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH